论文部分内容阅读
目的 研究成釉细胞瘤中p1 6mRNA的表达及其临床病理意义。方法 应用原位杂交方法研究分析了 47例成釉细胞瘤中p1 6mRNA的表达及其与临床病理参数的关系。 结果 32例良性成釉细胞瘤中 p1 6mRNA的阳性表达率为 71 .9% (2 3/32 ) ,恶性成釉细胞瘤中则为 40 .0 % (6/1 5) ,二者之间差异有统计学意义 (P <0 .0 5) ;p1 6mRNA表达与患者年龄、性别、肿瘤大小、部位无相关性 (P>0 .0 5) ;在 1 1例复发肿瘤和 36例无复发肿瘤中 ,p1 6mRNA阳性表达率分别为 36 .4% (4/1 1 )和 69.4% (2 5/36) ,二者间差异有统计学意义。结论 p1 6基因mRNA表达缺失与成釉细胞瘤的发生发展有关
Objective To study the expression of p1 6 mRNA in ameloblastoma and its clinicopathological significance. Methods The in situ hybridization method was used to analyze the expression of p1 6 mRNA in 47 patients with ameloblastoma and its relationship with clinicopathological parameters. Results The positive expression rate of p1 6 mRNA in 32 cases of benign ameloblastoma was 71.9% (2 3/32), while in malignant ameloblastoma 40.0% (6/1 5) The difference was statistically significant (P0.05). There was no correlation between the expression of p1 6 mRNA and age, gender, tumor size and site (P> 0.05). In 11 cases with recurrent tumor and 36 cases without recurrence The positive rates of p1 6 mRNA in tumors were 36.4% (4/1 1) and 69.4% (25/36), respectively. The difference was statistically significant. Conclusion The loss of p16 gene mRNA expression is associated with the development of ameloblastoma